Results 1 to 10 of about 747,376 (295)

Time to adjuvant chemotherapy after cytoreductive surgery and survival outcomes in epithelial ovarian cancer: a retrospective cohort study. [PDF]

Front Oncol
Jamdade K, Katsanevakis M, Njoku T, Tasnim N, Yaseen A, Ogundiran O, Subbiah S, Akram M, Gan C, Abu J, Santhanam S, Madhusudan S, Gajjar K.   +12 more
europepmc   +1 more source

Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer. [PDF]

Ther Adv Med Oncol
Cottu P, Pascual T, Lemonnier J, Hu H, Roux E, Connolly RM, Ma CX, Wolff AC, Crestani T, Tolosa P, Ferrero-Cafiero JM, Mulero-Sánchez A, Salvador F, Villacampa G, Gavilá J, de La Motte Rouge T, Prat A.   +16 more
europepmc   +1 more source

Oncotype DX-guided vs physician-directed chemotherapy and survival in HR+/HER2- breast cancer. [PDF]

Breast
Li J, Han X, Zhuang Y, Liu Y, Thomas SM, Plichta JK, Wang J, Lei B.   +7 more
europepmc   +1 more source

Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection. [PDF]

Cancer
Williams AD, Weiss A.
europepmc   +1 more source

The Promise of Machine Learning-Guided Adjuvant Chemotherapy for Resected Gallbladder Cancer. [PDF]

Gut Liver
Choi K.
europepmc   +1 more source

Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States. [PDF]

Breast Cancer Res Treat
Lynce F, Ru M, Luo L, Miranda M, Xu X, Isaacs C.   +5 more
europepmc   +1 more source

Paradigm Shifts in Perioperative Management of Colorectal Cancer: Personalization Based on Tumor Biology, Primary Site, and Recurrence Risk, and the Evolving Role of Organ Preservation. [PDF]

Int J Mol Sci
Yoshikawa K, Ooki A, Shinozaki E, Toyokawa E, Suzuki K, Shiozawa M, Maeda S, Yamaguchi K, Osumi H.   +8 more
europepmc   +1 more source

Advocating for Precision Neoadjuvant and Subsequent Adjuvant Therapies in Esophageal Squamous Cell Carcinoma: Evidence From a Real-World Multicenter Study. [PDF]

MedComm (2020)
Wang P, Wei X, Yu Y, Zhao Z, Ge Q, Lian J, Xing W, Li X, Li Y.   +8 more
europepmc   +1 more source

Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial. [PDF]

Signal Transduct Target Ther
Liu YT, Tang L, Han XH, Song ZY, Liu DR, Cheng G, Xiao WH, Zhang SC, Hu Y, Zhang L, Liu JF, Wang J, Dong GL, Shi YK.   +13 more
europepmc   +1 more source

A real-world multicenter study on postoperative adjuvant treatment patterns and prognostic implications following neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma. [PDF]

Front Immunol
Zhang X, Gao H, Cao J, Gao M, Xu Y, Zhang W, Qian P, Liu X, Fu Z, Shen W.   +9 more
europepmc   +1 more source